Tumor, Solid Clinical Trial
Official title:
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors
This clinical trial is a study of an experimental drug called BDB001. BDB001 is a Toll-like receptor (TLR) agonist that activates the immune system. The primary objectives of this study are to evaluate the safety and tolerability of BDB001 as a single agent and in combination with pembrolizumab and to determine the maximum tolerated dose (MTD) or the recommended Phase 2 dose (RP2D) when given in combination with pembrolizumab in subjects with advanced solid tumors. This is a multi-center, open-label, dose escalation/dose expansion Phase 1 study of BDB001 as a single agent and in combination with pembrolizumab in subjects with histologically-confirmed, incurable, unresectable or metastatic solid tumors that have relapsed or are refractory to standard therapies or for whom there is no approved therapy. The study will be conducted in two separate but independent dose escalation arms: a single agent arm (BDB001 alone) and a combination arm (BDB001 in combination with pembrolizumab). Participants will be allowed to continue treatment beyond study termination until occurrence of significant treatment-related toxicity, progressive disease or discontinuation criteria are met. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05637034 -
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
|
N/A | |
| Terminated |
NCT04095091 -
Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR)
|
||
| Recruiting |
NCT05378425 -
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
|
Phase 1 | |
| Not yet recruiting |
NCT04723810 -
TumorGlow Intraoperative Molecular Imaging (IMI)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06116032 -
Immune Profiling for Cancer Immunotherapy Response
|
||
| Recruiting |
NCT06090266 -
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04416165 -
Comparison of FDG and FAPI in Patients With Various Types of Cancer
|
N/A | |
| Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04750772 -
Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer
|
N/A | |
| Recruiting |
NCT06022029 -
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
|
Phase 1 | |
| Terminated |
NCT01358331 -
A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)
|
Phase 1 | |
| Recruiting |
NCT06175221 -
Autologous TLPO Vaccine Basket
|
Phase 2 | |
| Recruiting |
NCT05661461 -
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
|
Phase 1 | |
| Active, not recruiting |
NCT04196530 -
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
|
Phase 1 | |
| Not yet recruiting |
NCT03731390 -
GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT03491631 -
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06193902 -
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04528836 -
First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05221320 -
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
|
Phase 2 |